FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2199277501> ?p ?o ?g. }

• W2199277501 abstract "Safety and efficacy of primaquine against repeated attacks of Plasmodium vivax depends upon co-administered blood schizontocidal therapy in radical cure. We assessed primaquine (PQ) as hypnozoitocide when administered with dihydroartemisinin-piperaquine (Eurartesim®, DHA-PP) or artesunate-pyronaridine (Pyramax®, AS-PYR) to affirm its good tolerability and efficacy. A third arm, artesunate followed by primaquine, was not intended as therapy for practice, but addressed a hypothesis concerning primaquine efficacy without co-administration of blood schizontocide.During March to July 2013, an open-label, randomized trial enrolled Indonesian soldiers with vivax malaria at Sragen, Central Java, after six months duty in malarious Papua, Indonesia. No malaria transmission occurred at the study site and P. vivax recurrences in the 12 months following therapy were classified as relapses. A historic relapse control derived from a cohort of soldiers who served in the same area of Papua was applied to estimate risk of relapse among randomized treatment groups. Those were: 1) AS followed 2d later by PQ (0.5 mg/kg daily for 14d); 2) co-formulated AS-PYR concurrent with the same regimen of PQ; or 3) co-formulated DHA-PP concurrent with the same regimen of PQ.Among 532 soldiers, 219 had vivax malaria during the four months following repatriation to Java; 180 of these were otherwise healthy and G6PD-normal and enrolled in the trial. Subjects in all treatment groups tolerated the therapies well without untoward events and cleared parasitemia within three days. First relapse appeared at day 39 post-enrollment, and the last at day 270. Therapeutic efficacy of PQ against relapse by incidence density analysis was 92 % (95 %CI = 83-97 %), 94 %(95 %CI = 86-97 %), and 95 %(95 %CI = 88-98 %) when combined with AS, AS-PYR, or DHA-PP, respectively.This trial offers evidence of good tolerability and efficacy of PQ against P. vivax relapse when administered concurrently with DHA-PP or AS-PYR. These offer alternative partner drugs for radical cure with primaquine. The AS arm demonstrated efficacy with a total dose of 7 mg/kg PQ without concurrently administered blood schizontocide, another option when primaquine therapy is removed in time from the treatment of the acute malaria or applied presumptively without an attack.Current Controlled Trials ISRCTN82366390, assigned 20 March 2013." @default.
• W2199277501 created "2016-06-24" @default.
• W2199277501 creator A5003635603 @default.
• W2199277501 creator A5008927207 @default.
• W2199277501 creator A5016423112 @default.
• W2199277501 creator A5020721525 @default.
• W2199277501 creator A5034219102 @default.
• W2199277501 creator A5034748835 @default.
• W2199277501 creator A5038807888 @default.
• W2199277501 creator A5043515519 @default.
• W2199277501 creator A5047507055 @default.
• W2199277501 creator A5061309607 @default.
• W2199277501 creator A5066080831 @default.
• W2199277501 creator A5068237755 @default.
• W2199277501 creator A5071652312 @default.
• W2199277501 creator A5073369701 @default.
• W2199277501 creator A5076750976 @default.
• W2199277501 creator A5080326501 @default.
• W2199277501 date "2015-12-01" @default.
• W2199277501 modified "2023-10-10" @default.
• W2199277501 title "Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia" @default.
• W2199277501 cites W138982484 @default.
• W2199277501 cites W1476993096 @default.
• W2199277501 cites W1590890055 @default.
• W2199277501 cites W1755250673 @default.
• W2199277501 cites W1969834934 @default.
• W2199277501 cites W1977291996 @default.
• W2199277501 cites W1990484619 @default.
• W2199277501 cites W199510873 @default.
• W2199277501 cites W2005415125 @default.
• W2199277501 cites W2068476392 @default.
• W2199277501 cites W2072894930 @default.
• W2199277501 cites W2094572671 @default.
• W2199277501 cites W2096415021 @default.
• W2199277501 cites W2100026093 @default.
• W2199277501 cites W2100876932 @default.
• W2199277501 cites W2100970784 @default.
• W2199277501 cites W2103971948 @default.
• W2199277501 cites W2105607339 @default.
• W2199277501 cites W2107403206 @default.
• W2199277501 cites W2108429928 @default.
• W2199277501 cites W2117767554 @default.
• W2199277501 cites W2130272097 @default.
• W2199277501 cites W2130821869 @default.
• W2199277501 cites W2132107151 @default.
• W2199277501 cites W2134054893 @default.
• W2199277501 cites W2137862593 @default.
• W2199277501 cites W2137952006 @default.
• W2199277501 cites W2139242164 @default.
• W2199277501 cites W2152507925 @default.
• W2199277501 cites W2158149195 @default.
• W2199277501 cites W2158266463 @default.
• W2199277501 cites W2158624232 @default.
• W2199277501 cites W2159923524 @default.
• W2199277501 cites W2161252729 @default.
• W2199277501 cites W2166988212 @default.
• W2199277501 cites W2168652819 @default.
• W2199277501 cites W2168903926 @default.
• W2199277501 cites W2169647488 @default.
• W2199277501 cites W2220006073 @default.
• W2199277501 cites W48898854 @default.
• W2199277501 cites W83284349 @default.
• W2199277501 doi "https://doi.org/10.1186/s12916-015-0535-9" @default.
• W2199277501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4676167" @default.
• W2199277501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26654101" @default.
• W2199277501 hasPublicationYear "2015" @default.
• W2199277501 type Work @default.
• W2199277501 sameAs 2199277501 @default.
• W2199277501 citedByCount "46" @default.
• W2199277501 countsByYear W21992775012016 @default.
• W2199277501 countsByYear W21992775012017 @default.
• W2199277501 countsByYear W21992775012018 @default.
• W2199277501 countsByYear W21992775012019 @default.
• W2199277501 countsByYear W21992775012020 @default.
• W2199277501 countsByYear W21992775012021 @default.
• W2199277501 countsByYear W21992775012022 @default.
• W2199277501 countsByYear W21992775012023 @default.
• W2199277501 crossrefType "journal-article" @default.
• W2199277501 hasAuthorship W2199277501A5003635603 @default.
• W2199277501 hasAuthorship W2199277501A5008927207 @default.
• W2199277501 hasAuthorship W2199277501A5016423112 @default.
• W2199277501 hasAuthorship W2199277501A5020721525 @default.
• W2199277501 hasAuthorship W2199277501A5034219102 @default.
• W2199277501 hasAuthorship W2199277501A5034748835 @default.
• W2199277501 hasAuthorship W2199277501A5038807888 @default.
• W2199277501 hasAuthorship W2199277501A5043515519 @default.
• W2199277501 hasAuthorship W2199277501A5047507055 @default.
• W2199277501 hasAuthorship W2199277501A5061309607 @default.
• W2199277501 hasAuthorship W2199277501A5066080831 @default.
• W2199277501 hasAuthorship W2199277501A5068237755 @default.
• W2199277501 hasAuthorship W2199277501A5071652312 @default.
• W2199277501 hasAuthorship W2199277501A5073369701 @default.
• W2199277501 hasAuthorship W2199277501A5076750976 @default.
• W2199277501 hasAuthorship W2199277501A5080326501 @default.
• W2199277501 hasBestOaLocation W21992775011 @default.
• W2199277501 hasConcept C126322002 @default.
• W2199277501 hasConcept C168563851 @default.
• W2199277501 hasConcept C197934379 @default.
• W2199277501 hasConcept C203014093 @default.
• W2199277501 hasConcept C2775867548 @default.

• next